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Abstract 
Food allergy is a major public health concern with avoidance of the trigger food(s) being 
central to management by the patient. Food information legislation mandates the declaration 
of allergenic ingredients; however, the labelling of the unintentional presence of allergens is 
less defined. Precautionary allergen labelling (PAL) was introduced by the food industry to 
help manage and communicate the risk of reaction from the unintended presence of 
allergens in foods. In its current form, PAL is counterproductive for consumers with food 
allergies as there is no standardised approach to applying PAL. Foods with a PAL often do 
not contain the identified food allergen while some products without a PAL contain quantities 
of common food allergens that are capable of inducing an allergic reaction. Integrated 
Approaches to Food Allergen and Allergy Risk Management (iFAAM) was an EU-funded 
project that aimed to improve the management of food allergens by the food industry for the 
benefit of people with food allergies. Within iFAAM, a clinically validated tiered risk 
assessment approach for food allergens was developed. Two cross-stakeholder iFAAM 
workshops were held on 13th-14th December 2016 and 19th-20th April 2018. One of the 
objectives of these workshops was to develop a proposal to make PAL effective for 
consumers. This paper describes the outcomes from these workshops. This provides the 
basis for the development of more informative and transparent labelling that will ultimately 
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Background 
Food allergy is a major public health concern affecting up to 20 million European citizens, 
with high costs to public health services (1-5). Avoidance of the trigger food(s) is central to 
management by patients but accidental ingestion is common, causing frequent and 
sometimes life-threatening reactions (6-10). Admission rates for anaphylaxis have increased 
approximately 3-fold between 2005 and 2012 in several countries (11-13). Management of 
both food allergy (by patients and health practitioners) and allergens (by industry) is currently 
hindered by gaps in the evidence and in the implementation of our current knowledge 
compounded by a lack of consensus.  
 
Precautionary allergen labelling (PAL), often known as “may contain” labelling was 
introduced by the food industry to help manage and communicate the risk of reaction from 
the unintended presence of allergens in foods (recent review (14)). In its current form, PAL is 
counterproductive for consumers with food allergies as there is no standardised, consistent 
approach to applying PAL or to the wording that is used. Many products with a PAL do not 
contain the implicated food allergen while some products without a PAL contain quantities of 
common food allergens that are capable of inducing an allergic reaction in a significant 
proportion of the at-risk population (14-16). With this inconsistency, PAL has suffered a loss 
of credibility and trust and thus does not have the ability to facilitate an informed choice. This 
is important for consumers because these current practices result in poor confidence in 
coping, low perception of control, reduced observance of avoidance strategies, reduced 
quality of life, and increased risk by consumers who learn to disregard PAL. It is also 
important for food business operators, as it invalidates a valuable risk management and 
communication tool.  This is a situation that all stakeholders agreed needs to be urgently 
addressed. 
 
Integrated Approaches to Food Allergen and Allergy Risk Management (iFAAM) was an EU-
funded project that aimed to improve the management of food allergens by the food industry 
for the benefit of people with food allergies (17). The project aimed to develop holistic 
strategies to reduce the burden of food allergies in Europe and beyond, whilst enabling the 
European food industry to compete effectively in the global market place. The iFAAM 
approach has built on e-Health concepts to allow full exploitation of complex data obtained 
from the work in this project, maximising sharing and linkage of data. Within iFAAM, a 
clinically validated tiered risk assessment approach for food allergens was developed, with 
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Cross-stakeholder iFAAM workshops were held in Winchester (UK) on 13th-14th December 
2016 and Madrid (Spain) 19th-20th April 2018. One of the objectives of iFAAM was to 
develop a proposal to make PAL more effective for consumers (18). Stakeholder groups at 
the first meeting included healthcare practitioners, patient organisations, regulators 
(European Union Joint Research Centre –Institute for Reference Materials and 
Measurement, United Kingdom’s Food Standards Agency and Food Safety Authority 
Ireland), private sector and scientists (representation from European member states & 
United States). The final iFAAM project findings were reviewed and discussed at the second 
workshop.  This paper describes the different knowledge developed in iFAAM to help the 
food industry make PAL more transparent to consumers with allergies.    
 
The perspective of consumers with food allergies 
Patients and their parents live in fear of a life-threatening allergic reaction, where the threat 
is ever present but the chance and timing are unpredictable. This uncertainty can lead to 
extreme anxiety and avoidance on the one hand or frustration and risky behaviours on the 
other (19-21). Health related quality of life studies demonstrate a strong adverse impact for 
the child, teenager, adult and parent (22-27). Understanding patient responses to food safety 
issues is crucial to effective food safety policy and risk communication. It has become 
increasingly evident that consumers with food allergy are making decisions about the 
acceptability of specific foods, production technologies and both labelling format and text 
based on a complex interaction of perceptions of risk and benefit (28,29). Research from 
both the general consumer and from the food allergy population can guide us when 
considering issues of acceptability, and the influence of uncertainty and ambiguity. 
Uncertainty refers to an individual’s doubt as to the correct or best option to choose when 
making a food choice. People generally adopt a precautionary stance in the face of 
uncertainty (30-35). The presence of uncertainty influences an individual’s perception of the 
risks involved with each potential option; increasing the perceived risk in the situation 
(35,36). Ambiguity occurs when information is missing that could be essential to the 
decision-making process. PAL are helpful if they provide reliable and meaningful information 
on the allergen content. As current PAL use cannot be associated with any specific level of 
risk, both uncertainty and ambiguity are reinforced (13). 
 
Using action levels to better inform precautionary allergen labelling  
Reference doses have been developed to guide labelling decisions in the Voluntary 
Incidental Trace Allergen Labelling (VITAL™) system originally deployed in Australia (37,38). 
Reference doses refer to the amount of allergen that most (usually set at 95 or 99%) 
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(14). With information about the size of a typical meal of the specific food product, the 
reference dose can be used to calculate the concentration of allergen (action level) that is 
likely not to cause a reaction in 95 or 99% of the population with allergy. These action levels 
are specific for individual products. Action levels and quantitative risk assessment are now 
being used by food authorities in other countries, for example in Germany (39), Japan (40) 
and Belgium (41). However, due to the lack of official consensus, these action levels differ 
across countries resulting in divergent levels of risk for the food-allergic population in the 
various jurisdictions. This is not very helpful for consumers with food allergies and food 
industries. If these health related reference doses are more widely adopted by regulators 
and the food industry, the presence of a PAL statement would be tied to a defined level and 
probability of reacting, allowing patients to make informed choices with a reduced chance of 
experiencing an allergic reaction (14).   
 
The key challenge here for stakeholders is to develop effective risk-benefit communication 
that takes account of the majority of consumers with food allergy, while protecting 
particularly vulnerable groups. Past research with patients has shown that lack of 
awareness, confusion, and ‘talking past each other’ are reported as major barriers to the use 
and application of reference doses (31,42). Addressing scientific uncertainty and providing 
adequate information emerged as prerequisites to consumers with food allergy being 
receptive to their use. Information provision, such as appropriate and consistent label 
information, was considered essential, particularly by more risk tolerant individuals, to inform 
their food choices (31,42).  
 
Effective management of the risk from allergens must integrate multiple perspectives from 
different groups of consumers with food allergy (parents, adults, adolescents, those above 
and below certain eliciting dose thresholds), together with input from all relevant 
stakeholders (industry, retailers, scientists, health professionals, regulators, patient groups) 
in order to develop effective, coherent and creative risk-benefit communications to promote 
the acceptability of quantitative risk assessment in food manufacturing and labelling.  
 
Current labelling regulations and the challenges with the current approach 
In Europe, the legislation defines a list of 14 foods as the most prevalent allergens across 
Europe. Whenever they, or their derivatives are used in food and drink as ingredients or 
processing aids, they must be declared on the label or information made available to the 
consumer to enable them to make a safe and informed food choice (43,44). These rules 
build on the previous requirements for prepacked foods by introducing new requirements for 
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and for those to be emphasised from other ingredients within the ingredients list of 
prepacked foods and information to be made available for non-prepacked foods such as 
meals in a restaurant.  
 
The approach for the unintentional presence of allergens following agricultural or 
manufacturing cross-contamination is less well defined in legislation. At present there are no 
specific rules governing the unintentional presence of allergens in food, although there are 
provisions within the regulation (43) that could address this issue if invoked. The application 
of PAL such as ‘may contain’ is therefore understood to be defined by Article 14 (2) (3b) and 
(4c) of the ‘EU General Food Law’ Regulation (EC) No. 178/2002 in that food must not be 
unsafe or injurious to health and that information should be made available to enable 
consumers to avoid an adverse health effect. However, what is unsafe and injurious to 
health can vary across different countries and the interpretation of the “EU General Food 
Law” and its target groups as well as across the allergic population as individuals can vary 
greatly in their level of sensitivity to food allergens. Due to the heterogeneity and variability in 
sensitivities to allergens there has been little agreement on what level is ‘safe’ and ‘not 
injurious to health’. This has caused confusion and uncertainty among food regulators, the 
food industry and most importantly the food allergic consumer. The result has been the 
proliferation of PAL in terms of the proportion of products affected, as well as the diversity of 
PAL statements (45). The frequency with which the various types of PAL statements are 
used and their inconsistent application can lead the allergic consumer down the path of an 
unsubstantiated risk assessment and/or risk taking behaviour (14). 
 
Given that the use of PAL remains a technological necessity, the challenge for regulators 
and other stakeholders is to agree, internationally, on what allergen threshold will minimise 
the public health risk from unintentional allergen presence to consumers with food allergies. 
 
iFAAM risk assessment and management tools  
Currently, there is no consensus on an easy-to-use, widely available and generally 
applicable risk assessment tool for food allergens in Europe to help food producers ensure 
that foods do not contain more than the recognised safe level of allergen. iFAAM has worked 
on a risk assessment framework that enables an evaluation of the allergen risks pertaining to 
a production line, process or factory. The framework comprises three elements: allergen 
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Figure 1. iFAAM food allergen risk assessment framework.  
 
RA: risk assessment; PAL: precautionary allergen labelling.  
 
The allergen tracking tool provides a simple guidance (or tool) to help food business 
operators make an initial qualitative assessment for any allergen about its potential 
unintended presence at any point during the production process. The basis is the hazard 
analysis critical control point approach and the developed allergen tracking tool will assist 
food business operators to start unintended allergen presence risk analysis and incorporate 
it in their hazard analysis critical control point plans (more details at 
http://new.moniqa.org/risk-assessment-tools). An extension of the tool covers a vulnerability 
analysis of the supply chain to highlight potential sources of allergen contamination. The 
allergen tracking tool is presented as a decision tree to guide users through the risk analysis 
steps and can help the company decide whether a more quantitative assessment of allergen 
risk is needed.  
 
The Tier 1 risk assessment aims to provide an initial quantitative risk screen (46). The risk 
assessment is based on a comparison of the potential exposure to the unintended allergen 
with the sensitivity of the allergic population, to provide a binary ‘safe / not safe’ outcome. 
Within iFAAM, consumption data from three different European databases (NL, DK and FR) 
were combined into food groups for allergen risk assessment purposes (47). For other 
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sensitivity of the allergic population are the reference doses derived by Taylor et al for 
VITAL™ (37) (see also above in paragraph on reference doses) complemented with the 
threshold dose information from EuroPrevall (48). The contamination value will be provided 
by the users of the tool and should take into account the uncertainty around that 
contamination value. The Tier 1 risk assessment tool developed can be readily applied by 
food business operators of all sizes, without special expertise. It incorporates a significant 
degree of conservatism in its underlying assumptions.  
 
Whereas the Tier 1 risk assessment is based on point estimates for the consumption, the 
contamination and threshold levels, the Tier 2 risk assessment uses probabilistic methods to 
integrate all the available data and knowledge and to reflect variability and uncertainty (for 
example, taking into account the possibility of particulate contamination). The Tier 2 risk 
assessment therefore provides a full quantitative risk estimate (49). Compared to Tier 1, Tier 
2 is more sophisticated and requires specific training and experience to use effectively. The 
basis was the probabilistic model already designed within TNO, French Agency for Food, 
Environmental and Occupational Health & Safety and Food Allergy Research 
and Resource Program and further developed during the course of the iFAAM project (50-
52).  
 
The total risk assessment framework envisages an iterative process, whereby the results of 
the initial analysis in the allergen tracking tool lead to mitigating measures and/or Tier 1 risk 
assessment, following which the risk is re-analysed by re-running the tools. Tier 2 risk 
assessment is applied when a fully quantitative analysis would be beneficial, for instance, 
when the tier 1 risk assessment would indicate an unsafe situation and when comparing risk 
mitigation measures and evaluating their feasibility. 
 
Quantity, measurement and reporting  
Being able to measure allergen concentrations in food ingredients is essential for a risk 
assessment to deliver safe food for the consumer with allergies (53). This requires an 
analysis of food allergen proteins that is valid, accurate and reproducible. Allergen levels 
should be the definition of quantity as ‘amount of substance’ (milligrams, or concentration, 
mg/kg or millimoles/kg). There needs to be agreement on what is actually being measured 
which will dictate the system calibrators, quality control materials or reference materials 
(Table 1). Traceability to the International System of Units, Système international d'unités 













This article is protected by copyright. All rights reserved. 
 
 
Table 1 Suggested examples of analytical targets, what is measured, calibrants and 
reference materials 
Target What is measured 
(measurand) 
Calibrants Quality control or 
reference material 
Enzyme-linked immunosorbent assay 
A protein or group of 
proteins 
What the capture 
antibody was raised to 
OR 
A well characterised 
protein molecule 
OR 
A selected amino acid 
sequence 
Serial dilutions of a 
well-defined extract of 






concentration of the 





material food such as 
skimmed milk powder 
or defatted light 
roasted peanut flour 
from which in-house 
quality control 
materials can be made 
Liquid chromatography–tandem mass spectrometry 




epitope or epitope 
fragments or peptides 
Synthesised peptides 
or purified allergen 
protein 
As above and 
isotopically labelled  
Peptides 
Real time polymerase chain reaction 
(deoxyribonucleic 
acid) DNA 
DNA copy number  Serial dilutions of 
extracted DNA in DNA 




Total allergen protein concentrations for suggested clinically relevant reference materials are 
available (37,38) and can be used to derive concentrations (action levels) for any desired 
consumption amount. For example the VITAL Reference Dose for peanut of 0.2 mg peanut 
protein suggests a clinically relevant concentration of 2 mg/kg peanut protein for a 100g 
serving (53). Analytical systems should achieve limits of detection and limits of quantification 
sufficiently low for statistically meaningful validation. Table 2 shows examples of 
performance criteria along with data, derived from kit inserts for commercial ELISAs for 
peanut and egg. It can be seen that ELISAs are available for peanut protein with the 
required sensitivity although not all platforms seem able to achieve the desired criteria. For 
egg protein, commercial ELISAs struggle to meet the desired criteria albeit there have been 
anecdotal suggestions that the reference dose for egg protein may be unrealistically low 
owing to the use of raw egg in challenge studies. It is also possible to assess actual egg 
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ELISAs may not currently achieve the criteria suggested by the egg reference dose. 
Adequate validation, third party accreditation and participation in relevant proficiency testing 
schemes are key to assuring the quality of analytical results. A further important aid is the 
inclusion in any analytical strategy of relevant positive controls containing the allergen of 
interest in the matrix in which it occurs. This is straightforward for food manufacturers to 
carry out during analysis of their own products, both in-house and by their contract 
laboratories but not easy for enforcement laboratories to accommodate. 
 

















Limit of quantification 
(mg kg
-1
 allergen protein) 
Limit of detection (mg kg
-
1










       




0.25 – 2 
(c) 
 
0.07 0.05 – 0.5 
(c) 
       




0.3 – 0.7 
(c) 
0.01 0.03 – 0.3 
(c) 
    0.4 – 5.5 
(d)  
 0.1 – 1.8 
(d) 
       
(a) Target concentration, as milligrams allergen protein per kilogram food consumed, to note if the 
portion size is greater e.g. a typical ready meal or take-away meal of 500 g target concentration  
reduces to 0.4 mg kg
-1
 allergen protein and 0.06 mg kg
-1
 allergen protein for peanut and egg 
respectively 
(b) Analytical systems should achieve limits of detection and limits of quantification sufficiently below 
the target concentration for method validation allowing estimation of false positive (α error) and false 
negative (β error) likelihoods at a 95 % confidence interval. As a rule of thumb a limit of quantification 
of one tenth of the target concentration should yield the desired interval with the limit of detection 
lower again by a factor of 3 
(c) Based on ELISA kit inserts 
(d) Calculated from data in ref. 54 by                                and                    
      where x  and s  are the mean and standard deviation of measurements of blank (no template) 
controls.  
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A new approach to precautionary allergen labelling: patient perspective 
In a recent survey conducted by patient organisations (57), the majority of consumers with 
food allergies in 16 countries were not prepared to buy or eat a food if they knew that it may 
contain a certain amount of their allergen, even if they knew that this food would only elicit 
mild symptoms or indeed no symptoms at all. This is not surprising, since patients and 
parents have been educated by healthcare professionals as well as patient organisations to 
strictly avoid their allergen to be safe (9). ‘Just a little bit(e) can hurt’ raises vigilance but also 
creates anxiety regarding the unintended consumption of the culprit food. If consumers with 
food allergy were informed about the disadvantages of the current situation (lack of 
transparency and consistency of the applied method for allergen risk assessment and the 
related uncertainty for consumers to make informed decisions), they may feel that a 
consistent and transparent approach for allergen risk assessment based on scientific data 
would be more advantageous. This is the approach taken in a quantitative risk assessment. 
Based on an understanding that a guarantee of zero risk is not feasible for food, allergic 
consumers agreed during a German stakeholder conference in Berlin, November 2015, that 
an acceptable risk for them would be to know, that they or their children might only have a 
(low) risk of experiencing a mild reaction like itching, hives, nausea or even vomiting (42). It 
is acknowledged that the generalisability of this needs to further assessed.  
 
iFAAM precautionary allergen labelling survey 
The iFAAM PAL survey was developed for adults and parents of children with food allergy 
(DunnGalvin et al, submitted). The aim was to help us to understand more about how those 
living with food allergy assess risk when making decisions based on PAL (‘may contain’), 
attitudes to current labelling practice and to the potential use of quantitative risk assessment 
in manufacturing. Over 1,500 respondents (UK, Germany, Netherlands, Spain, Poland) 
completed the survey. The results showed that a significant number of adults with food 
allergy or parents of children with food allergy perceive that if a PAL is not on a product, this 
implies that the product is safe to eat (with those who ‘never’ consult PAL more likely to 
endorse this option). Overall, there was a low level of confidence in PAL in helping adults 
and children avoid allergic reactions. The results also showed that a transparent and 
consistent quantitative risk assessment process, if used to make a decision about whether to 
include ‘may contain’, would greatly increase trust in a product, particularly for parents and 
those with ‘low confidence’ in labelling. If a PAL statement had to be applied, ‘not suitable 
for’ was rated the ‘most preferred’ option, among several phrases presented, including 
‘accidental presence of [allergen]’; and ‘may contain [allergen]’. A combination of statements 
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unintended allergen presence + risk assessment statement + risk assessment symbol), 
compared to each separately, was rated as ‘most useful’ across groups, including subgroups 
such as those who do not at present consult PAL, those with low confidence in PAL, those 
reporting the most severe reactions, those who have experienced previous anaphylactic 
reactions, and parents of young children. . The outcomes from this research (Figure 2) can 
guide us when considering issues of acceptability and provide a basis for the development of 











Figure 2. Factors influencing emerging attitudes towards level of risk 
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The central message for industry is that there must be a clear indication on a food product 
that a quantitative risk assessment has been carried out to inform the inclusion of a PAL on 
a product. Furthermore, we must have a clear consensus across stakeholders about what 
the presence or the absence of a PAL means in terms of the safety of the product (14).  At 
present, patients cannot obtain this information by consulting the label and both healthcare 
professionals and patient organisations have no clear indication on how to guide a patient or 
parent on the absence of labelling, which is currently ambiguous about whether a product 
can be considered safe for them or not.  
 
At the iFAAM workshop, the patient groups felt that a regulated approach was required, 
perhaps as an extension of Regulation 1169/2011 (43). This would make it mandatory for 
each food business operator to undertake a risk assessment and apply or not apply a PAL 
according to evidence based reference doses. If a voluntary approach was to be taken, there 
would need to be agreement across the food industry with a clear indication on the food 
label that a quantitative risk assessment had been applied.  Adequate and harmonised 
explanatory information, training, and multiple forms of dissemination are crucial when 
providing any new forms of risk management, and this is particularly important in the case of 
vulnerable populations such as those with food allergy.  
 
A new approach to precautionary allergen labelling: health care professional 
perspective 
Clinicians at the workshops perceived that there is a lack of understanding, confusion and 
cynicism about food manufacturing and PAL among health care professionals, which poses 
difficulty in providing useful and informed advice to patients.  Communication at an individual 
level on risk management in different contexts, such as eating out is a challenge for 
clinicians, particularly with existing time restraints in consultation.  In the context of improving 
allergen management for people with food allergies, acceptable risk can only be properly 
defined on a population (public health) basis. Therefore, there was consensus that we 
should begin by evaluating the acceptability of mild reactions, limited to one organ system, 
i.e. those symptoms which result in no or minimum interference with daily activities. In this 
context, acceptability needs to factor in not only the reaction characteristics, but also the 
burden of uncertainty that many people with food allergies experience. 
 
Dose distribution data are now available for many priority allergenic foods. Single dose 
challenge studies, recently completed for peanut (58), will be extremely useful to 
characterize the risk associated with ingestion of a known low dose of an allergenic food. 
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to that dose (as established by dose distributions) but would also reveal the spectrum of 
reactions experienced. Such data should help to improve the trust that consumers with food 
allergy need in the scientific data underpinning quantitative limits. Acceptable risk is crucially 
dependent on the trust of those at risk. Improvement in risk assessment (c.f. Tier 1 approach 
from iFAAM) is therefore critical and the outcomes of those tools need to integrate the latest 
scientific findings and be interpreted in the context of any extrinsic factor effect (e.g. asthma 
control, exercise) with consideration of a safety margin being added if there is unacceptable 
uncertainty.   
 
Last but not least, the clinical group stressed that any consensus on acceptable risk needs 
to evolve as new data and knowledge become available; the process will thus always be 
iterative. 
 
Applying the new iFAAM approach to precautionary allergen labelling  
How could the food industry implement the iFAAM tiered risk approach?  
The Winchester workshop felt that the implementation of the risk assessment approach by 
the food industry could begin through bodies such as FoodDrinkEurope (organisation 
representing European food businesses) as an industry-wide approach. This could be 
achieved by developing guidance around  implementation and integrating it into existing 
tools used to manage food safety issues, such as hazard analysis critical control point plans. 
A “check mark” on food packaging would be required to show that it had been through an 
accepted risk assessment process. The use of such a check-mark would need to be tied into 
appropriate and ongoing training to accredit the process. In parallel the workshop felt that 
there was a need to improve the quality of allergen analytical methods with regards the 
sensitivity required to measure allergens below the reference doses and reduce the variance 
of analytical methods (currently much higher than would be accepted for other chemical 
hazards).  
 
To facilitate this approach, there was a need to improve the quality and transparency of 
reporting of analytical test results, with clearly defined test performance criteria, and a 
requirement for reporting units to be expressed in total protein (the allergenic hazard). In 
addition there was a need for agreed conversion factors, reference materials and sampling 
plans.  
 
It was felt that the support of retailers would be needed in the implementation phase and it 
was unclear how the application of the risk assessment process would be viewed by food 
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would need to take a lead on this but that once implementation had begun there would likely 
be interest from international bodies such as Codex Alimentarius.  
 
Lastly, there is a need to engage regulators. Across the EU there is an inconsistent 
approach to food allergen risk assessment and management with some member states 
applying a risk based approach and others a “zero tolerance” approach. There is an urgent 
need for DG Santé and the European Food Safety Authority to address the concerns of the 
Member States in this regard and initiate a process to identify whether the iFAAM tiered risk 
assessment approach can be considered appropriate across Europe.  
 
What does the iFAAM tiered risk approach mean in terms of risk for individual consumers 
with food allergy?  
Being able to accurately measure allergen concentrations in food ingredients is essential to 
deliver safe food for the consumer with allergies. At present, there is a low level of 
confidence in the ability of PAL to help adults and children avoid allergic reactions and, as 
PAL cannot be associated with any specific level of risk, consumers experience uncertainty 
and constant worry about buying and eating food products. The iFAAM risk assessment 
framework, and easy to use tools will enable a systematic and consistent evaluation of the 
allergen risks pertaining to a production line, process or factory. A standardised applied risk 
tool which can ensure that foods do not contain more than the recognised safe level of 
allergen, would greatly increase trust in a product if used as a basis to make a decision 
about whether to apply a PAL warning. Although different types of products need different 
methods of analyzing for risk (e.g. processed versus commodity products), the same 
standards can be applied with the message being that a quantitative risk assessment has 
been carried out on a product to inform whether a label is applied or not applied. So the 
presence as well as the absence of a PAL actually has a tangible meaning in terms of the 
safety for the consumer.  
 
How can we better help patients to utilise labelling? 
From the survey conducted by iFAAM  it is evident that consumers with food allergies prefer 
a clear indication on the food label regarding both an actual risk of unintended allergen 
presence indicated by PAL as well as a reference on the food as to whether a quantitative 
risk assessment has been carried out by word and logo. Representatives from industry at 
the workshop felt that they had to balance needs from the general population versus those 
from consumers with food allergy. However it was also recognised that subgroup interests 
are accepted and catered for in general by industry.  Providing clear information on labelling 
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currently viewed as ‘more risky’ in terms of safety by those with food allergy. The information 
on food packaging must be relevant, meaningful and cater to the needs of those with a food 
allergy. Although different types of products need different methods of analyzing for risk (e.g. 
processed versus commodity products), the same standards should be applied. The PAL 
should clearly indicate whether a quantitative risk assessment has been carried out on a 
product to inform the decision on whether a label is applied or not applied. At present 
consumers cannot obtain this information from consulting the label and healthcare 
professionals and patient organisations have no clear indication on how to guide a patient or 
parent on the absence of PAL (14).  
 
How can healthcare professionals better help patients to utilise labelling? 
Healthcare professionals, as well as patients, need to be educated about quantitative risk 
assessment and PAL and how individual patients can use this approach depending on their 
personal threshold. Population thresholds need to be explained within this context and linked 
to individual thresholds. ‘Single dose’ challenges (58) can help to reassure all stakeholders 
on the validity of the science and help individual patients make better informed food 
decisions. In addition they can be used to assess the risk for the individual patient. This 
information should be integrated across clinical (diagnosis, reactions) and real life 
(management) contexts.  In this way, those who are at low risk and those who are at high 
risk, according to their personal threshold and clinical history, can feel confident in 
undertaking a personal risk assessment and management plan that works for them. Training 
and education is vital and must be consistent and standardized across all stakeholders. This 
will help patients to ask the right questions and help industry, healthcare professionals and 
retailers to answer them in the right way, and with confidence. We can learn from the 
experience in Australia with the take up of VITAL 2.0™ (37,38,59).  When expectations were 
raised among consumers, industry felt that these expectations should be met. The widest 
acceptance across stakeholders would be achieved when the use of when and how to apply 
PAL is regulated by law.  
 
Summary  
The four year iFAAM project has worked to make precautionary allergen labelling 
transparent. The consortium has surveyed consumers and the food industry to understand 
the current situation. To assist health care professionals and patients navigate the current 
system, the consortium has published short online guides for patients and healthcare 
professionals (18). Groups in the consortium have developed a two-tiered approach that 
provides much improved risk assessment and management tools to inform the consistent 
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data on reaction thresholds collected in the EuroPrevall and iFAAM projects and beyond. 
Such an approach has the potential to provide allergic consumers with the accurate and 
reliable information that they need to decide what is safe for them to eat. Much work is still 
required. It will also be impossible to provide a 100% guarantee of safety especially with the 
variability induced by intrinsic and extrinsic cofactors. A consistent regulatory approach is 
required, initially across Europe. The European food industry bodies need to be involved to 
ensure that this can be implemented industry wide to provide a consistent picture for allergic 
consumers to navigate. Finally, with the interconnectivity across the world, a global initiative 
would be ideal.    
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